相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry
Oliver Sartor et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?
Chen-Lung Ku et al.
HUMAN GENETICS (2020)
Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology
Kathy Kamath et al.
SCIENTIFIC REPORTS (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
Rana R. McKay et al.
ADVANCES IN THERAPY (2020)
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Carolina Lucas et al.
NATURE (2020)
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Karim Fizazi et al.
EUROPEAN UROLOGY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Qian Zhang et al.
SCIENCE (2020)
IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Christopher J. Sweeney et al.
CANCER RESEARCH (2020)
The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis
Zicheng Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn et al.
EUROPEAN UROLOGY (2019)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer
Harsimar B. Kaur et al.
HUMAN PATHOLOGY (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+T regulatory cells
Thiago Vidotto et al.
PROSTATE (2019)
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
Celestia S. Higano et al.
CANCER (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The in silico human surfaceome
Damaris Bausch-Fluck et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Differential regulation of Effector and Regulatory T cell function by Blimp1
Rashmi Bankoti et al.
SCIENTIFIC REPORTS (2017)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
Debraj GuhaThakurta et al.
CLINICAL CANCER RESEARCH (2015)
Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer
Giorgio Gandaglia et al.
EUROPEAN UROLOGY (2015)
Charting the human proteome: Understanding disease using a tissue-based atlas
M. Uhlen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Michael A. Postow et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Merritt P. Edlind et al.
ASIAN JOURNAL OF ANDROLOGY (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Human syndromes of immunodeficiency and dysregulation are characterized by distinct defects in T-cell receptor repertoire development
Xiaomin Yu et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
Lawrence Fong et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
Nadeem A. Sheikh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients
Kelly G. Paulson et al.
CANCER RESEARCH (2010)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Shihua Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
Ricardo M. Attar et al.
CLINICAL CANCER RESEARCH (2009)
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
Luiz Gonzaga Almeida et al.
NUCLEIC ACIDS RESEARCH (2009)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
